Ring Sulfur In The Additional Hetero Ring Patents (Class 514/342)
-
Patent number: 11655246Abstract: Compounds of formula (I): (I) and related aspects.Type: GrantFiled: November 30, 2018Date of Patent: May 23, 2023Assignee: STEP PHARMA S.A.S.Inventors: Abdul Quddus, Andrew Novak, David Cousin, Elli Chatzopoulou, Emma Blackham, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
-
Patent number: 11639351Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.Type: GrantFiled: February 24, 2021Date of Patent: May 2, 2023Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 11578066Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.Type: GrantFiled: April 28, 2022Date of Patent: February 14, 2023Assignee: Tenaya Therapeutics, Inc.Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
-
Patent number: 11319313Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.Type: GrantFiled: May 7, 2021Date of Patent: May 3, 2022Assignee: Poxel SAInventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
-
Patent number: 11319317Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: November 16, 2020Date of Patent: May 3, 2022Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Patent number: 11291655Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.Type: GrantFiled: July 11, 2018Date of Patent: April 5, 2022Assignee: Cyteir Therapeutics, Inc.Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca
-
Patent number: 11261180Abstract: The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.Type: GrantFiled: December 18, 2018Date of Patent: March 1, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Peter Tai Wah Cheng, Yan Shi, Hao Zhang
-
Patent number: 11213516Abstract: The present invention relates to field of intravaginally applicable devices that release antiviral compounds. In particular, the present invention relates to vaginal rings comprising a matrix releasing at least one antivirally active compound, in particular anti-herpetic compound N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide (in the following also referred to as “Pritelivir”) or salts thereof. The present invention therefore relates to the treatment and prevention of herpes infections.Type: GrantFiled: June 28, 2018Date of Patent: January 4, 2022Assignee: AICURIS GMBH & CO. KGInventors: Yogeshwar Bachhav, Susanne Bonsmann, Tamara Pfaff, Alexander Birkmann, Karl Malcolm
-
Patent number: 11141411Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.Type: GrantFiled: December 6, 2018Date of Patent: October 12, 2021Assignee: Poxel SAInventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
-
Patent number: 11091472Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 24, 2017Date of Patent: August 17, 2021Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 11071736Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.Type: GrantFiled: April 30, 2018Date of Patent: July 27, 2021Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
-
Patent number: 11021474Abstract: The present invention relates to the field of anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide as well as methods for the manufacture thereof. The present invention relates also to the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.Type: GrantFiled: November 28, 2017Date of Patent: June 1, 2021Assignee: AiCuris Anti-Infective Cures GmbHInventors: Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Kurt Voegtli
-
Patent number: 10945998Abstract: A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.Type: GrantFiled: March 8, 2016Date of Patent: March 16, 2021Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Sanford Markowitz, Stanton Gerson, Amar Desai, Won Jin Ho
-
Patent number: 10940143Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: GrantFiled: August 5, 2019Date of Patent: March 9, 2021Assignee: Poxel SAInventor: Anthony W. Czarnik
-
Patent number: 10844126Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.Type: GrantFiled: July 31, 2018Date of Patent: November 24, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
-
Patent number: 10588909Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.Type: GrantFiled: March 11, 2015Date of Patent: March 17, 2020Assignees: Taivex Therapeutics Corporation, Development Center For BiotechnologyInventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
-
Patent number: 10576071Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: GrantFiled: March 12, 2018Date of Patent: March 3, 2020Assignee: Poxel SAInventor: Anthony W. Czarnik
-
Patent number: 10512622Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.Type: GrantFiled: July 11, 2018Date of Patent: December 24, 2019Assignee: CymaBay Therapeutics, Inc.Inventors: Pol Boudes, Charles A. McWherter
-
Patent number: 10376518Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.Type: GrantFiled: March 28, 2014Date of Patent: August 13, 2019Assignee: UCL BUSINESS PLCInventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
-
Patent number: 10251852Abstract: Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPAR? agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.Type: GrantFiled: April 11, 2017Date of Patent: April 9, 2019Assignee: Children's Hospital Medical CenterInventors: Bruce Trapnell, Tony Sallese, Brenna Carey, Takuji Suzuki
-
Patent number: 10227360Abstract: The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases.Type: GrantFiled: February 18, 2015Date of Patent: March 12, 2019Assignee: Piramal Enterprises LimitedInventors: Sanjay Kumar, Rajiv Sharma, Somnath Halder, Sangameshwar Prabhakar Sawargave, Vijaykumar Bhagwan Deore
-
Patent number: 10183015Abstract: This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.Type: GrantFiled: March 3, 2016Date of Patent: January 22, 2019Assignee: Medivation Technologies LLCInventors: Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha
-
Patent number: 10172837Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.Type: GrantFiled: September 26, 2016Date of Patent: January 8, 2019Assignee: Naia Metabolic, Inc.Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
-
Patent number: 10034868Abstract: The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.Type: GrantFiled: November 4, 2014Date of Patent: July 31, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DESCARTESInventors: Pierre-Louis Tharaux, Carole Henique Greciet, Guillaume Bollee
-
Patent number: 9925175Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: GrantFiled: April 1, 2016Date of Patent: March 27, 2018Assignee: DeuteRx, LLCInventor: Anthony W. Czarnik
-
Patent number: 9782395Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.Type: GrantFiled: May 5, 2016Date of Patent: October 10, 2017Assignee: MINORYX THERAPEUTICS S.L.Inventors: Ana María García Collazo, David John Augustus Eckland, Maria Pilar Pizcueta Lalanza, Marc Martinell Pedemonte
-
Patent number: 9701638Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.Type: GrantFiled: November 8, 2013Date of Patent: July 11, 2017Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. Lavoie, Joseph David Bauman, Hye Yeon Sagong, Eddy Arnold, Ajit Parhi, Kalyan Das, Suyambu Kesava Vijayan, Disha Patel
-
Patent number: 9701675Abstract: Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPV4 inhibitor. Further provided are compositions including a TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application. Further provided is a transgenic mouse whose genome includes deletions of the Trpv4 gene in keratinocytes of the epidermis, wherein said transgenic mouse is a knockout for the Trpv4 gene in keratinocytes of the epidermis following keratinocyte-specific activation and expression of a site-specific recombination enzyme.Type: GrantFiled: February 8, 2016Date of Patent: July 11, 2017Assignees: Duke University, The Regents of the University of CaliforniaInventors: Wolfgang Liedtke, Martin Steinhoff, Farshid Guilak
-
Patent number: 9670197Abstract: Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R?, X, or NR1R2; R? is R3, or OR3; R? is R4, or OR4; R1 and R2 are each independently H, alkyl, or acyl; R3 is H, heteroaryl, or alkyl; R4 is H, heteroaryl, or CnH2n+1 (n>2); and X is F, Br, I, CN, or NO2. In some embodiments, compounds having a molecular structure according to Formula 1 have the property of inhibiting a growth of a cell line selected from HeLa and MB468 with a sub-micromolar IC50.Type: GrantFiled: July 8, 2016Date of Patent: June 6, 2017Assignee: The Regents of the University of CaliforniaInventors: Wen-Hwa Lee, Jiewen Zhu, Chun-Mei Hu
-
Patent number: 9643963Abstract: The invention relates to 1,2,4-thiadiazole derivatives and their use to treat parasites.Type: GrantFiled: November 14, 2014Date of Patent: May 9, 2017Assignee: Avista Pharma Solutions, Inc.Inventors: Hao Liu, Jessica Marie Sligar, Jason Daniel Speake, Joseph A. Moore, III, Brent Christopher Beck
-
Patent number: 9592225Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.Type: GrantFiled: August 31, 2015Date of Patent: March 14, 2017Assignee: AICURIS ANTI-INFECTIVE CURES GMBHInventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
-
Patent number: 9566269Abstract: Modified release pharmaceutical compositions of epalrestat are provided. Methods of manufacturing the tablets and treating various diseases and conditions, including diabetes and diabetic complications, by administering the modified release compositions to patients in need thereof are also provided.Type: GrantFiled: January 20, 2012Date of Patent: February 14, 2017Assignee: Bionevia Pharmaceuticals Inc.Inventors: Isabel Kalofonos, Judy Caron, William Martin-Doyle
-
Patent number: 9550764Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof for use in the treatment of cancer:Type: GrantFiled: August 22, 2013Date of Patent: January 24, 2017Assignee: The Institute of Cancer Research: Royal Cancer HospitalInventors: Keith Jones, Matthew David Cheeseman, Spyridon Linardopoulos, Amir Faisal, Olivier Remi Barbeau, Andrew Kalusa
-
Patent number: 9527838Abstract: Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.Type: GrantFiled: December 12, 2013Date of Patent: December 27, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Emma R. Parmee, Jiayi Xu
-
Patent number: 9499503Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.Type: GrantFiled: April 6, 2015Date of Patent: November 22, 2016Assignee: Array BioPharma Inc.Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R. Laird, John Robinson, Shelley Allen
-
Patent number: 9447033Abstract: The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X1, R1, R2, R3, R4, and R5 are defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.Type: GrantFiled: May 28, 2015Date of Patent: September 20, 2016Assignee: Japan Tobacco Inc.Inventors: Mushtaq Mulla, Derek Edward John, Richard John Hamlyn, Sasha Louise Garrett, Basil Hartzoulakis, David Madge, John Ford
-
Patent number: 9409902Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.Type: GrantFiled: October 29, 2014Date of Patent: August 9, 2016Assignee: Taivex Therapeutics CorporationInventors: Johnson Lau, Jiann-Jyh Huang
-
Patent number: 9346770Abstract: Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPAR?,?,?) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPAR?,?,?).Type: GrantFiled: June 18, 2011Date of Patent: May 24, 2016Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Yaping Wang, Guojun Zheng, Peng Sun, Yi Li, Yingqiu Wu, Bin Liu, Xiaoyu Liu, Hua Bai, Hongyan Li, Xiaohe Zheng
-
Patent number: 9339543Abstract: Pharmaceutical formulations comprising solid pharmaceutically acceptable organic acids, such as maleic acid or tartaric acid, that inhibit the disproportionation of pharmaceutically acceptable acid salts of active pharmaceutical ingredients, and methods of manufacturing such pharmaceutical compositions. The pharmaceutically acceptable acid salt of the active pharmaceutical ingredient has a pKa of less than about 6.0, and wherein the solid pharmaceutically acceptable organic acid has a pKa of less than about 4.0 and an aqueous solubility in the range of about 500 to about 2000 milligrams per milliliter. A pharmaceutical formulation comprising a pharmaceutical acceptable acid salt of pioglitazone, a solid pharmaceutically acceptable organic acid selected from the group consisting of maleic acid or tartaric acid, and an excipient that promotes disproportionation, wherein the ratio by weight of the solid pharmaceutically acceptable organic acid to excipient is from about 1:6 to about 1:1.Type: GrantFiled: October 8, 2012Date of Patent: May 17, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher T. John, Paul A. Harmon
-
Patent number: 9301952Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: GrantFiled: April 20, 2011Date of Patent: April 5, 2016Assignee: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Patent number: 9212179Abstract: The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.Type: GrantFiled: June 20, 2014Date of Patent: December 15, 2015Assignee: Baylor College of MedicineInventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Mizuki Watanabe
-
Patent number: 9192603Abstract: Heterocyclic sulfone compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.Type: GrantFiled: May 12, 2011Date of Patent: November 24, 2015Assignee: Vanderbilt UniversityInventors: P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Colleen M. Niswender, Rocco D. Gogliotti, James M. Salovich, Darren W. Engers, Yiu-Yin Cheung
-
Patent number: 9126992Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.Type: GrantFiled: August 5, 2014Date of Patent: September 8, 2015Assignee: Romark Laboratories, L.C.Inventors: Jean-Francois Rossignol, J. Edward Semple
-
Patent number: 9102666Abstract: Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.Type: GrantFiled: January 9, 2012Date of Patent: August 11, 2015Assignees: ZINFANDEL PHARMACEUTICALS, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Allen D. Roses, Rajneesh Taneja
-
Patent number: 9040704Abstract: Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.Type: GrantFiled: August 10, 2012Date of Patent: May 26, 2015Assignee: UTI LIMITED PARTNERSHIPInventors: Warren Edward Piers, Juan Felipe Araneda
-
Publication number: 20150141433Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.Type: ApplicationFiled: September 26, 2014Publication date: May 21, 2015Inventors: David R. Anderson, Robert A. Volkmann
-
Publication number: 20150141428Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
-
Patent number: 9034871Abstract: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.Type: GrantFiled: April 13, 2012Date of Patent: May 19, 2015Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz
-
Patent number: RE46724Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.Type: GrantFiled: May 17, 2016Date of Patent: February 20, 2018Assignee: Romark Laboratories, L.C.Inventors: Jean-Francois Rossignol, J. Edward Semple
-
Patent number: RE47786Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.Type: GrantFiled: January 8, 2018Date of Patent: December 31, 2019Assignee: Romark Laboratories L.C.Inventors: Jean-Francois Rossignol, J. Edward Semple